10.7 C
London
Tuesday, May 28, 2024

Anbio Launches Revolutionary “Point of Care” Technology across Europe

Anbio Biotechnology is making strides in the European sector with its flagship offering, the AF-100 C, an innovative compact fluorescent immunoassay analyser set to transform point-of-care diagnostics. Boasting more than 70 assays, the AF-100 C is designed to bolster healthcare provision within the EU, thereby improving patient outcomes and prognoses.

Anbio Biotechnology (Anbio), a foremost entity in in vitro diagnostics globally, is thrilled to unveil its expansive “Point of Care” product line within the European Union. This initiative signifies a pivotal development for Anbio, heralding new opportunities for partnership with EU distributors and healthcare practitioners and showcasing the firm’s commitment to delivering state-of-the-art diagnostic solutions in the EU.

Anbio, renowned for its innovative spirit and excellence, has evolved beyond its reputation as a supplier of Covid testing kits to become a versatile producer and innovator of a broad array of diagnostic tools. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” stated Michael Lau, Anbio’s CEO.

Innovative Analyzer Provides Access to Over 70 Essential Tests

At the heart of Anbio’s EU promotional efforts lies the AF-100 C analyzer, a cutting-edge, single-channel, mobile, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This advanced instrument, coupled with over 70 CE-approved assays for a variety of analytes including inflammation markers, diabetes, cancer markers, hormones, enzymes, and infectious diseases, promises to reshape the EU’s clinical diagnostics landscape.

“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau further remarked. Despite its diminutive stature, the AF-100 C offers high throughput and is perfectly adapted for diverse clinical environments, from private practices to A&E departments. Its intuitive interface and a durable battery allowing up to 8 hours of uninterrupted testing, empowers medical staff to deliver superior patient care with efficiency and efficacy.

Prompt, Precise Diagnostics Enhance Patient Health Outcomes

Anbio’s extensive FIA range, capable of yielding swift results within 3 to 15 minutes, marks a significant advancement in diagnostic technologies. With reagents employing RFID chip technology to ensure precision, and capable of being stored at room temperature for up to two years, Anbio is well-positioned to address the immediate demands of Europe’s healthcare sector.

As Anbio Biotechnology cements its presence in the EU market, it extends an invitation to distributors and healthcare professionals to discover its groundbreaking diagnostic solutions. Committed to elevating patient care through affordable, accurate, and dependable diagnostics, Anbio is eager to forge partnerships with healthcare experts throughout the EU.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

More Stories

Related Articles